Astria Therapeutics Inc (ATXS)

Currency in USD
12.580
+0.080(+0.64%)
Closed·
Showing Astria Therapeutics historical data. For real-time data please try another search
Fair Value
Day's Range
12.44512.590
52 wk Range
3.55513.290
Key Statistics
Prev. Close
12.58
Open
12.48
Day's Range
12.445-12.59
52 wk Range
3.555-13.29
Volume
3.2M
Average Volume (3m)
1.08M
1-Year Change
69.7706%
Book Value / Share
2.44
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATXS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.333
Upside
+61.63%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Astria Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Astria Therapeutics Inc Company Profile

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. As of January 23, 2026, Astria Therapeutics, Inc. operates as a subsidiary of BioCryst Pharmaceuticals, Inc.

Compare ATXS to Peers and Sector

Metrics to compare
ATXS
Peers
Sector
Relationship
P/E Ratio
−5.8x−3.9x−0.6x
PEG Ratio
0.680.090.00
Price/Book
5.2x5.8x2.6x
Price / LTM Sales
1,017.2x62.6x3.4x
Upside (Analyst Target)
3.3%230.3%41.8%
Fair Value Upside
Unlock−6.8%4.8%Unlock

Analyst Ratings

1 Buy
4 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 20.333
(+61.63% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 12, 2025
EPS / Forecast
-0.55 / -0.42
Revenue / Forecast
706.00K / 12.80M
EPS Revisions
Last 90 days

ATXS Income Statement

People Also Watch

23.200
CAPR
-4.01%
473.83
SNDK
-5.88%
63.41
CYTK
-2.34%
11.99
ORIC
-0.50%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.